Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Cash & Equivalents of $110.7 million for Q1 2026, up 61.29% year-over-year from $68.7 million in Q1 2025, and down 8.61% quarter-over-quarter from $121.2 million in Q4 2025.
Aquestive Therapeutics (AQST) Cash & Equivalents (2017 - 2026) Analysis & Trends
Aquestive Therapeutics' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $110.7 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 61.29% year-over-year to $110.7 million; the TTM figure through Mar 2026 stood at $110.7 million (up 61.29% YoY), while the FY2025 annual figure was $121.2 million, up 69.36% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $110.7 million, down from $121.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $129.1 million in Q3 2025, with the low at $14.7 million in Q1 2022.
- The 5-year median for Cash & Equivalents is $60.5 million (2025), against an average of $58.9 million.
- The sharpest annual moves came in 2022 and 2024: Cash & Equivalents slumped 48.31% in 2022, then surged 300.56% in 2024.
- Aquestive Therapeutics' Cash & Equivalents stood at $27.3 million in 2022, then slipped by 12.47% to $23.9 million in 2023, then jumped by 199.71% to $71.5 million in 2024, then jumped by 69.36% to $121.2 million in 2025, then slipped by 8.61% to $110.7 million in 2026.
- Business Quant data shows AQST's Cash & Equivalents at $110.7 million in Q1 2026, $121.2 million in Q4 2025, and $129.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 164.00 Mn |
| 10 | Aquestive Therapeutics | 554.35 Mn | 554.35 Mn | 9.80 Mn | 98.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.49 Mn |
| Mar 31, 2026 | 110.73 Mn |
| Dec 31, 2025 | 121.17 Mn |
| Sep 30, 2025 | 129.06 Mn |
| Jun 30, 2025 | 60.54 Mn |
| Mar 31, 2025 | 68.66 Mn |
| Dec 31, 2024 | 71.55 Mn |
| Sep 30, 2024 | 77.89 Mn |
| Jun 30, 2024 | 89.87 Mn |
| Mar 31, 2024 | 95.20 Mn |
| Dec 31, 2023 | 23.87 Mn |
| Sep 30, 2023 | 24.92 Mn |
| Jun 30, 2023 | 22.44 Mn |
| Mar 31, 2023 | 26.88 Mn |
| Dec 31, 2022 | 27.27 Mn |
| Sep 30, 2022 | 18.65 Mn |
| Jun 30, 2022 | 17.70 Mn |
| Mar 31, 2022 | 14.74 Mn |
| Dec 31, 2021 | 28.02 Mn |
| Sep 30, 2021 | 31.16 Mn |